MindNerves Technology Competitors

Neuralink is a neurotechnology company building a generalized input/output platform for the brain. Our work has the potential to restore autonomy to those with unmet medical needs and fundamentally transform how humans interact with the world. Our core technology is an implantable brain-computer interface with ultra-thin, flexible electrode threads placed precisely by a surgical robot, enabling high-bandwidth, bidirectional interaction with neural signals. We’ve received multiple FDA Breakthrough Device designations and are conducting clinical trials around the world. Trial participants are exploring how our implant could enhance their daily lives — controlling digital devices like computers and smartphones, operating physical devices like robotic arms and wheelchairs, and translating thought directly into speech and text. Developing brain-computer interfaces is an interdisciplinary challenge, and we’re looking for exceptional talent across engineering, science, and operations. Explore opportunities to contribute to our mission at neuralink.com/careers.

ENABLING NEUROTECHNOLOGY Paradromics builds brain-computer interface (BCI) technologies for seamless human-technology integration, designed to restore and enhance human capabilities. By capturing brain activity at the resolution of individual neurons, our high-data-rate platform creates a foundation for the most advanced BCI applications. With each new application, we will create human capabilities that transcend disabilities, and eventually, biology itself. THE MISSION Data-driven BCI-based technologies for brain health Our technology will help millions with unmet medical needs suffering from paralysis and movement disorders to chronic pain, addiction, depression and other mental health conditions. ABOUT Matt Angle Ph.D. (CEO) founded Paradromics to build a high-data-rate BCI platform capable of addressing critical unmet clinical needs. With early funding from the NIH and DARPA, the company developed its core neurotechnology and, by 2019, shifted focus to its first product: the Connexus® BCI. Connexus is designed to restore communication through text, synthesized speech, and computer control for people with severe motor impairments, including those caused by ALS, stroke, or spinal cord injury. Backed by two FDA Breakthrough Device Designations and a successful first-in-human recording in May 2025, Paradromics achieved its first human implantation of the Connexus BCI as part of the FDA-approved Connect-One study in June 2026, marking a major milestone toward delivering its first product to people living with severe motor impairment.

BrainCo’s leadership draws on deep experience in neuroscience research and expertise in education to deliver entirely new applications of brainwave technology in the education, wellness, and research spaces. We’ve learned important lessons as we’ve grown from a small team in an apartment basement to over 100 employees in 4 offices around the world. Since 2015 we’ve been working on providing the best experience possible for our customers and we’re here to share our progress and innovations with you.